Natalie Mattis
Research Subjects
Research Interests
Natalie Mattis has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Anna M. Rose
Department of Genetics, UCL Institute of Ophthalmology, London, UK
1 shared publication - Ester M. Hammond
Department of Oncology, University of Oxford, Oxford, UK
1 shared publication Kanggeon Kim
Department of Oncology, University of Oxford, ORCRB, Roosevelt Drive , Oxford , OX3 7DQ
1 shared publicationTomas Goncalves
Department of Paediatrics, University of Oxford, John Radcliffe Hospital, Headley Way , Oxford , OX3 9DU
1 shared publication
Latest Publications
- Open Access
- 1 August 2025
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 34 (19) , 1638-1647
Silencing of SOD1 sensitises ATRX-deficient cells to camptothecin treatment through increased activity of the alternative lengthening of telomeres pathway
The alternative lengthening of telomeres (ALT) pathway is a telomere maintenance mechanism that is driven by formation of DNA double-strand breaks at telomeres. ALT-positive malignancies often have mutational deletion of ATRX, but formation of DNA-protein complexes (DPCs) and elevated reactive oxygen species (ROS) also play a role in the induction of the ALT pathway. It has been recognised that excessive ALT activation can lead to rapid cell death, due to genome instability. Our objectives were to assess whether combining ROS-forming and DPC-forming treatments had a synergistic effect in ATRX-deficient cells. We found that SOD1 silencing was an effective method for inducing cell death in ATRX-deficient osteosarcoma cell lines; further, this approach was more effective in ATRX-null HeLa-LT than ATRX-wildtype cells. We also observed that dual treatment with DPC-forming chemotherapy (camptothecin) and SOD1 silencing led to a significantly higher level of DPCs, as well as signs of ALT pathway overactivity. Finally, our investigation demonstrated that pre-treatment of ATRX-null cells with shSOD1 significantly increased cellular sensitivity to camptothecin, with synergy between the two treatments. This research provides critical understanding to inform new treatment approaches—which might eventually improve survival for affected individuals, and reduce long-term effects, for survivors of ALT-positive malignancies.
- 1 August 2025
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 34 (19) , 1638-1647
Open AccessSilencing of SOD1 sensitises ATRX-deficient cells to camptothecin treatment through increased activity of the alternative lengthening of telomeres pathway
The alternative lengthening of telomeres (ALT) pathway is a telomere maintenance mechanism that is driven by formation of DNA double-strand breaks at telomeres. ALT-positive malignancies often have mutational deletion of ATRX, but formation of DNA-protein complexes (DPCs) and elevated reactive oxygen species (ROS) also play a role in the induction of the ALT pathway. It has been recognised that excessive ALT activation can lead to rapid cell death, due to genome instability. Our objectives were to assess whether combining ROS-forming and DPC-forming treatments had a synergistic effect in ATRX-deficient cells. We found that SOD1 silencing was an effective method for inducing cell death in ATRX-deficient osteosarcoma cell lines; further, this approach was more effective in ATRX-null HeLa-LT than ATRX-wildtype cells. We also observed that dual treatment with DPC-forming chemotherapy (camptothecin) and SOD1 silencing led to a significantly higher level of DPCs, as well as signs of ALT pathway overactivity. Finally, our investigation demonstrated that pre-treatment of ATRX-null cells with shSOD1 significantly increased cellular sensitivity to camptothecin, with synergy between the two treatments. This research provides critical understanding to inform new treatment approaches—which might eventually improve survival for affected individuals, and reduce long-term effects, for survivors of ALT-positive malignancies.